1. Home
  2. VRTX vs MDT Comparison

VRTX vs MDT Comparison

Compare VRTX & MDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRTX
  • MDT
  • Stock Information
  • Founded
  • VRTX 1989
  • MDT 1949
  • Country
  • VRTX United States
  • MDT Ireland
  • Employees
  • VRTX N/A
  • MDT N/A
  • Industry
  • VRTX EDP Services
  • MDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • VRTX Technology
  • MDT Health Care
  • Exchange
  • VRTX Nasdaq
  • MDT Nasdaq
  • Market Cap
  • VRTX 128.5B
  • MDT 116.9B
  • IPO Year
  • VRTX 1991
  • MDT N/A
  • Fundamental
  • Price
  • VRTX $467.01
  • MDT $87.62
  • Analyst Decision
  • VRTX Buy
  • MDT Hold
  • Analyst Count
  • VRTX 29
  • MDT 16
  • Target Price
  • VRTX $513.58
  • MDT $94.07
  • AVG Volume (30 Days)
  • VRTX 1.2M
  • MDT 5.9M
  • Earning Date
  • VRTX 11-04-2024
  • MDT 11-19-2024
  • Dividend Yield
  • VRTX N/A
  • MDT 3.19%
  • EPS Growth
  • VRTX N/A
  • MDT 9.56
  • EPS
  • VRTX N/A
  • MDT 2.97
  • Revenue
  • VRTX $10,625,800,000.00
  • MDT $32,577,000,000.00
  • Revenue This Year
  • VRTX $12.20
  • MDT $4.92
  • Revenue Next Year
  • VRTX $8.31
  • MDT $4.77
  • P/E Ratio
  • VRTX N/A
  • MDT $29.50
  • Revenue Growth
  • VRTX 10.06
  • MDT 3.23
  • 52 Week Low
  • VRTX $346.29
  • MDT $74.66
  • 52 Week High
  • VRTX $519.88
  • MDT $92.68
  • Technical
  • Relative Strength Index (RSI)
  • VRTX 42.88
  • MDT 43.49
  • Support Level
  • VRTX $489.02
  • MDT $85.01
  • Resistance Level
  • VRTX $519.88
  • MDT $92.03
  • Average True Range (ATR)
  • VRTX 14.86
  • MDT 1.59
  • MACD
  • VRTX -2.67
  • MDT -0.31
  • Stochastic Oscillator
  • VRTX 14.49
  • MDT 37.18

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About MDT Medtronic plc.

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.

Share on Social Networks: